Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

Bristol Myers Squibb (NYSE: BMY) today announced meaningful progress toward its global inclusion & diversity goals and health equity commitments, meeting and exceeding some goals ahead of schedule. In 2020, Bristol Myers Squibb (BMS) and the Bristol Myers Squibb Foundation, an independent charitable organization, each committed $150 million over five years, totaling $300 million to address health equity efforts by 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005232/en/

BMS and the Foundation are on track to achieve many of their respective goals and have exceeded some ahead of schedule. Progress against the four priority areas include:

• Health Equity: BMS has made measurable progress against its goal to award $150 million to address health disparities. Nearly $100 million in distributed funding has reached more than 10 million people through programs and services. BMS is announcing $10 million in grants during 2023 to 17 U.S. organizations focused on addressing social determinants of health, including healthcare access and literacy to help close gaps and increase access to healthcare.
  
  

• Increasing clinical trial diversity: In less than two years, more than half— 58%— of BMS’ clinical trial sites are now located in racially and ethnically diverse areas. This surpasses BMS’ initial goal of 25%. By embedding more clinical trial sites in diverse communities, BMS is helping enroll clinical trial populations that are more reflective of the broader patient populations and aligned with the epidemiology of the diseases we study.
  
  

• Diversifying suppliers: BMS achieved its goal of spending $1 billion globally with diverse-owned businesses that create jobs and generate positive economic impact in diverse communities ahead of plan. This is against the company’s original goal to reach $1 billion in spending globally with diverse-owned businesses by 2025. Sustaining and building on this achievement will remain a priority. Investing in diverse suppliers enables BMS to close economic and healthcare gaps in diverse communities.
  
  

• Diversifying company workforce: BMS has also made meaningful progress against the aspirational workforce representation goals announced in 2020, including the following:
  
  
  
  
  • More than doubled Black/African American executive (Vice President and above, VP+) representation in the U.S. to 6.1% from 3%, just exceeding the goal of reaching 6% by 2022
    
    
    
  • Increased the representation of global female executives (VP+) from 38.9% to 48.7%, nearly a 10% increase in two years, just below the goal of 50% by 2022
    
    
    
  • Increased the representation of Hispanic/Latino executives (VP+) in the U.S. from 3.7% to 6.1%, just below goal of 7.4% by 2022

BMS is announcing new aspirational workforce representation goals for Executive Directors and above (ED+) to strengthen our internal pipeline of talent and the next generation of leadership at BMS. These goals include:

• Increase the representation of African/American Black leaders at the Executive Director level and above in the U.S. to 10% by end of 2025
  
  
  
• Increase the representation of Hispanic/Latino leaders at Executive Director level and above in the U.S. to 11% by end of 2025

BMS achieved gender parity in the overall workforce population in 2015 and is close to achieving gender parity at the executive levels. Although BMS is not establishing forward-looking representation goals for employees who are female, Asian American and Pacific Islander, or employees that represent additional dimensions of diversity at this time, the company remains fully committed to the development, advancement and engagement of these groups. BMS believes this approach enables the company to engage a broader set of experiences, backgrounds and perspectives to drive equitable outcomes for all.

“Inclusion, diversity and health equity are not just our values; they are a critical driver of business performance with accountability owned by everyone,” said Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol Myers Squibb. “Our expanded goals will enable us to drive a greater impact and build a more equitable future for our patients, colleagues, communities and industry.”

“Our global inclusion, diversity and health equity goals are accelerating our progress towards integrating inclusive practices into processes, policies and systems to ensure we are addressing the root causes of inequity,” said Pamela Fisher Chief Inclusion and Diversity Officer, Bristol Myers Squibb.

As part of the company's health disparity commitments, the additional nearly $10 million in health equity grants will be dispersed among 17 U.S. nonprofit organizations in 2023. These organizations address social determinants of health across BMS’ key therapeutic areas, cardiovascular disease, hematology, oncology and immunology. These grants support various organizations working to improve health in the U.S. These organizations are developing and implementing innovative approaches and partnerships for addressing social determinants of health and integrating social care and healthcare to reduce health disparities.

The Foundation has also made significant progress against its goal to award $150 million to address health equity through a three-pronged approach. The Winn Award Program, established by the Foundation with a $100 million commitment, is currently training 114 early-stage investigator physicians, and it has provided an immersive experience in community-based clinical research to 44 medical students who will support the goals of advancing clinical research in underserved patient communities. The Foundation has awarded $45 million supporting thirty-two grants to advance health equity in cancer, cardiovascular disease, and immunology. The Foundation has also mobilized approximately $1 million in employee donations supporting social justice organizations.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Corporate Philanthropy-News

View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005232/en/